RA Capital Management’s Scribe Therapeutics SCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33.2M Buy
+1,802,178
New +$47.5M 0.33% 44

Other funds holding SCTX

RA Capital Management's SCTX Position: Q3 2026 in Review

RA Capital Management opened a new position in Scribe Therapeutics (SCTX) in Q3 2026: 1,802,178 shares worth $33.2M. The stake represents 0.33% of the portfolio and ranks #44 among its holdings.

62 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.

  • RA Capital Management held 1,802,178 shares of Scribe Therapeutics worth $33.2M as of Q3 2026.
  • Scribe Therapeutics was a new RA Capital Management position in Q3 2026.
  • Scribe Therapeutics made up 0.33% of RA Capital Management's portfolio in Q3 2026, its #44 holding.
  • 62 funds tracked by Wall St. Rank held Scribe Therapeutics as of Q3 2026.

Based on RA Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.